Mexostem is used to evaluate the interactions between stem cells and omnipotent monocytes (OPMs), as well as the effects of exosomes on both cell types and circulating tumor cells (CTCs), establishing personalized cellular analysis data and screening for exosome sources with superior cellular functional responses.
Through a stem cell and OPMs co-culture model, Mexostem evaluates the effects of exosomes from different sources on stem cell viability, while simultaneously testing the changes in CTC viability induced by exosomes. By integrating CTC subtyping results, it establishes objective exosome functional analysis data to assist professionals in personalized evaluations and strategic planning.
CTC Subtype Profiling employs proprietary cell expansion technology to culture circulating tumor cells (CTCs) and circulating hybrid cells (CHCs) from blood samples, utilizing flow cytometry to analyze eight major cancer cell types as a reference for cancer risk assessment, disease monitoring, and treatment response tracking.
Analyzing the cellular state and characteristics of stem cells and OPMs to understand their functional performance, establishing a stem cell and OPMs co-culture model as a foundation for subsequent functional analysis.
Combining exosomes from different sources with various peptide treatments to observe cellular viability and evaluate their impact on stem cell and OPMs activity. Simultaneously analyzes changes in CTC viability in response to different exosome sources, establishing exosome functional analysis data to serve as an essential reference for exosome functional evaluation and application planning.
Individuals who wish to understand differences in cellular responses to exosomes derived from different stem cell sources
Individuals who need to evaluate exosome functional performance as a reference for development of future application plan
Individuals who wish to understand differences in cellular responses to stem cell-derived exosomes from different sources after stem cell and OPMs co-culture
Collect approximately 60 mL of human peripheral blood at a partner institution. The specimen will be delivered to the laboratory within 24 hours to initiate subsequent cell culture and testing analysis.
Employ proprietary culture technology to culture and expand stem cells, OPMs, and CTCs to evaluate cellular state and perform exosome and peptide testing analysis.
Co-culture stem cells with OPMs and apply 4 different exosome sources along with 6 peptide drugs to test their impact on cell growth. Concurrently, apply the same drug combination to analyze changes in CTC viability.
Integrate and comprehensively analyze all test results to issue an exclusive test report, serving as an important reference for developing personalized treatment plans.
Report Delivered in Approximately 14 Working Days
